Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC50 of Dexmedetomidine in STN-DBS for Parkinson's Disease
NCT05376761Phase 4Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dexmedetomidine in Parkinson's disease (PD), sponsored by Beijing Tiantan Hospital. Primary endpoint: Median Effective Concentration (EC50) of Dexmedetomidine. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05376761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376761.